TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27785375

Group type: EXPERIMENTAL
Intervention: Bepotastine 10 mg tablets
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 28
Study: 25092936

Group type: EXPERIMENTAL
Intervention: Telephone peer counseling (4 or 8 contacts)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: No peer counseling
Number of subjects: 1948
Study: 22691101

Group type: EXPERIMENTAL
Intervention: Agrippal® (trivalent vaccine)
Number of subjects: 1893

Group type: COMPARATOR
Intervention: Fluvirin® (control trivalent vaccine)
Number of subjects: 1893
Study: 20130863

Group type: EXPERIMENTAL
Intervention: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No postoperative LT4 treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-deficient patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: No postoperative LT4 treatment among iodine-deficient patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-sufficient patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: No postoperative LT4 treatment among iodine-sufficient patients
Number of subjects: 150
Study: 18397716

Group type: EXPERIMENTAL
Intervention: Oral mizoribine (MZB) pulse therapy, 10.0-19.7 mg/kg/d, maximum total dose 750 mg, given twice a week before a meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral mizoribine (MZB) pulse therapy
Number of subjects: 16
Study: 15850469

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2b 1.5 mcg/kg plus oral ribavirin (1000 or 1200 mg/day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: interferon alpha-2b 3 MU t.i.w. plus ribavirin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2b plus ribavirin
Number of subjects: 153

Group type: COMPARATOR
Intervention: interferon alpha-2b plus ribavirin
Number of subjects: 153
Study: 12209378

Group type: EXPERIMENTAL
Intervention: High-vegetable diet
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline period (habitual diets)
Number of subjects: 37

Group type: COMPARATOR
Intervention: All study periods
Number of subjects: 37
Study: 10467191

Group type: EXPERIMENTAL
Intervention: Transradial catheterization
Number of subjects: 200
Study: 7598771

Group type: EXPERIMENTAL
Intervention: vCP125 (10^6 TCID50) followed by rgp160 formulated in alum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: vCP125 (10^6 TCID50)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rgp160 booster injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: rgp160 formulated in alum or in Freund's incomplete adjuvant (FIA)
Number of subjects: 20
Study: 2164070

Group type: EXPERIMENTAL
Intervention: 2% lonapalene ointment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 10
Study: 567008

Group type: EXPERIMENTAL
Intervention: Fish diet (mackerel)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control diet (full-fat cheese)
Number of subjects: 42
Study: 30767639

Group type: EXPERIMENTAL
Intervention: Self-care programme
Number of subjects: 61
Study: 30888959

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy for 23 months following one-month dual antiplatelet therapy (DAPT)
Number of subjects: 15991

Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 15991
Study: 27883927

Group type: EXPERIMENTAL
Intervention: ASH-P (cognitive-behavioral family-based alcohol, DSH, and HIV prevention program)
Number of subjects: 81
Study: 26089029

Group type: EXPERIMENTAL
Intervention: Cinacalcet (60 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg)
Number of subjects: 18
Study: 25252853

Group type: EXPERIMENTAL
Intervention: Mobile phone and web-based psychotherapy intervention
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 720
Study: 22643014

Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting healthy weight development
Number of subjects: 1418
Study: 19220754

Group type: EXPERIMENTAL
Intervention: exendin(9‐39)
Number of subjects: 10

Group type: COMPARATOR
Intervention: atropine
Number of subjects: 10
Study: 16839698

Group type: EXPERIMENTAL
Intervention: Enhanced Therapy group (n=27) with MEMS feedback and compliance enhancement counseling using CBT techniques
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual Care group (n=28) receiving weekly individual smoking cessation sessions only
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study: 15611571

Group type: EXPERIMENTAL
Intervention: Testosterone administration (testosterone enanthate, 600 mg/wk intramuscularly)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Acyline (GnRH antagonist)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Testosterone replacement with acyline
Number of subjects: 53
Study: 12039110

Group type: EXPERIMENTAL
Intervention: 25 microgram of 17 beta‐E2
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10 microgram of 17 beta‐E2
Number of subjects: 58
Study: 9003858

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (50 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 7963304

Group type: EXPERIMENTAL
Intervention: Epineurotomy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (non‐epineurotomy)
Number of subjects: 33
Study: 3625243

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 845

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 845
Study: 30036166

Group type: EXPERIMENTAL
Intervention: Home Telemonitoring (HTM) with weekly video televisits and daily vital sign monitoring
Number of subjects: 89

Group type: COMPARATOR
Intervention: Comprehensive Outpatient Management (COM) with weekly telephone contact
Number of subjects: 89
Study: 29374412

Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: High consumption of vegetables
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Positive FIT results (cut-off 100 ng/mL)
Number of subjects: 1060
Study: 26529073

Group type: EXPERIMENTAL
Intervention: Tdap (tetanus, diphtheria acellular pertussis) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetanus only vaccine (Control)
Number of subjects: 0
Study: 24781761

Group type: EXPERIMENTAL
Intervention: Cryoablation plus zoledronic acid
Number of subjects: 84

Group type: COMPARATOR
Intervention: Zoledronic acid alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cryoablation alone
Number of subjects: 84
Study: 22976996

Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 64

Group type: COMPARATOR
Intervention: Walking exercise
Number of subjects: 64
Study: 19996755

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR (biomarker)
Number of subjects: 103
Study: 17555928

Group type: EXPERIMENTAL
Intervention: E/E' ratio of early tricuspid inflow to annular diastolic velocity
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: E/E' ≥ 4
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Increase of greater than 2 in E/E'
Number of subjects: 101
Study: 15701590

Group type: EXPERIMENTAL
Intervention: MAS063D (Atopiclair)
Number of subjects: 30
Study: 12757067

Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg in normal saline 0.3 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 0.3 ml
Number of subjects: 40
Study: 11087061

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Tutorial training group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 8883232

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg dolasetron mesilate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg dolasetron mesilate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg dolasetron mesilate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate (all doses pooled)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate
Number of subjects: 50
Study: 1589561

Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg salmon calcitonin (sCT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 IU/kg salmon calcitonin (sCT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose of sCT
Number of subjects: 12
Study: 3890825

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3654291

Group type: EXPERIMENTAL
Intervention: Dog activity sessions
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dog activity sessions (12 weeks) followed by other activity (12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Other activity sessions
Number of subjects: 66
Study: 30391445

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) at maximum flow rate of 60 LPM and FiO2 of 0.36-0.40
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard Nasal Cannula (SNC) at 4 LPM
Number of subjects: 59
Study: 28385659

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg once weekly
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg once weekly
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 1225
Study: 25744362

Group type: EXPERIMENTAL
Intervention: Chewing xylitol gum (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No gum (control group, n = 28)
Number of subjects: 55
Study: 23743108

Group type: EXPERIMENTAL
Intervention: Use of magnetic positioning device (UPD) during colonoscopy
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Standard colonoscopy without UPD
Number of subjects: 1068
Study: 21343937

Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Further invitation to attend for cervical cytology
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: HPV positive women
Number of subjects: 3000
Study: 19730273

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for suicide prevention (CBT-SP)
Number of subjects: 110
Study: 16581479

Group type: EXPERIMENTAL
Intervention: Noninvasive Doppler tissue imaging (CMM DTI)
Number of subjects: 27
Study: 15318465

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 2.5 microg kg(‐1) during induction (Groups 2 and 4)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Physiological saline solution during induction (Groups 1 and 3)
Number of subjects: 120
Study: 10770181

Group type: EXPERIMENTAL
Intervention: Leu7Pro polymorphism (Pro7 substitution) in boys
Number of subjects: 688
Study: 9395949

Group type: EXPERIMENTAL
Intervention: Cardiotomy suction (CTR) system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cell-saver (CS)
Number of subjects: 16
Study: 8416595

Group type: EXPERIMENTAL
Intervention: Patient-controlled compression
Number of subjects: 109

Group type: COMPARATOR
Intervention: Technologist-controlled compression
Number of subjects: 109
Study: 3602017

Group type: EXPERIMENTAL
Intervention: 5 mg bendroflumethiazide plus 15 mmol potassium chloride
Number of subjects: 78

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 78
Study: 29464338

Group type: EXPERIMENTAL
Intervention: Calcium-magnesium-bicarbonate content in thermal mineral water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 27421987

Group type: EXPERIMENTAL
Intervention: Removable Partial Dentures (RPDs)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Shortened Dental Arch (SDA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: functionally orientated treatment (SDA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dental implant treatment
Number of subjects: 55
Study: 25035882

Group type: EXPERIMENTAL
Intervention: Facebook use
Number of subjects: 960

Group type: COMPARATOR
Intervention: Alternate internet site
Number of subjects: 960
Study: 22933438

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 548
Study: 20843224

Group type: EXPERIMENTAL
Intervention: 0.2 µg/kg/hr
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.4 µg/kg/hr
Number of subjects: 13
Study: 19253506

Group type: EXPERIMENTAL
Intervention: Nebulization
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MDI with Volumatic spacer
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DPI (Easyhaler)
Number of subjects: 54
Study: 16201856

Group type: EXPERIMENTAL
Intervention: Controlled family-based health education/counseling intervention (5 counseling sessions)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Control group 1 (no counseling)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Control group 2 (no counseling)
Number of subjects: 1055
Study: 12617332

Group type: EXPERIMENTAL
Intervention: Simultaneous ultra‐filtration (UF GROUP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isovolemic phase with sequential ultra‐filtration (ISO GROUP)
Number of subjects: 16
Study: 10334412

Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise echocardiography (SBE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Post-treadmill exercise echocardiography (TME)
Number of subjects: 74
Study: 7491878

Group type: EXPERIMENTAL
Intervention: Calcium supplement (17.85 mmol (714 mg)/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: UK mothers (high-calcium diet)
Number of subjects: 25
Study: 1697334

Group type: EXPERIMENTAL
Intervention: Intrathecal natural beta-IFN
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6267617

Group type: EXPERIMENTAL
Intervention: Pivmecillinam/pivampicillin (200 mg pivmecillinam and 250 mg pivampicillin, twice daily for 10 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim, twice daily for 10 days)
Number of subjects: 42
Study: 30097056

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI)
Number of subjects: 0
Study: 27505611

Group type: EXPERIMENTAL
Intervention: 500 mg dried ginger capsules twice daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 24158762

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with Coenzyme Q10
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saturated fatty acid-rich diet
Number of subjects: 20
Study: 22920077

Group type: EXPERIMENTAL
Intervention: Pollen grains plus starch granules
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Starch granules only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pollen grains
Number of subjects: 30
Study: 20133927

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study: 17478068

Group type: EXPERIMENTAL
Intervention: Achilles Insight QUS imaging device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements using Lunar Prodigy DXA scanner
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of BMD and QUS variables
Number of subjects: 60
Study: 16331126

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise at 60-70% of age-predicted maximal heart rate for 30 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quiet rest for 30 min
Number of subjects: 40
Study: 11948834

Group type: EXPERIMENTAL
Intervention: OptiMARK
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Magnevist
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study: 9655642

Group type: EXPERIMENTAL
Intervention: Tourniquet applied (tourniquet group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No tourniquet applied (non-tourniquet group)
Number of subjects: 97
Study: 8595643

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 5 mg once daily (titrated to 10 mg after 4 weeks)
Number of subjects: 0
Study: 2914082

Group type: EXPERIMENTAL
Intervention: Potassium (KCl; 20 mEq three times daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral calcium (Ca; 500 mg twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 14
Study: 30582240

Group type: EXPERIMENTAL
Intervention: Cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy
Number of subjects: 108
Study: 27230861

Group type: EXPERIMENTAL
Intervention: Group-based cognitive intervention (GCI)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Home-based cognitive intervention (HCI)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study: 25487930

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.05-0.1 µg·kg‐1·min‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no remifentanil)
Number of subjects: 24
Study: 23025735

Group type: COMPARATOR
Intervention: General practice‐based health‐check with brief lifestyle counselling and referral to a program with one to two individual visits with an exercise physiologist or dietitian, and six group sessions.
Number of subjects: 655

Group type: COMPARATOR
Intervention: Attended minimum number of group program sessions (117 patients, 30.5% of intervention group).
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 655
Study: 19484483

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) every 28 days with high-dose radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) every 28 days with reduced-dose radiotherapy
Number of subjects: 0
Study: 18728281

Group type: EXPERIMENTAL
Intervention: ACE inhibitors or ARBs
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: ACE inhibitors or ARBs initiated during the study
Number of subjects: 1051
Study: 16483027

Group type: EXPERIMENTAL
Intervention: Rice bran oil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Refined sunflower oil
Number of subjects: 14
Study: 12072043

Group type: EXPERIMENTAL
Intervention: Oestrogen supplementation (oestradiol valerate 1 mg daily, n = 7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 12
Study: 9164902

Group type: EXPERIMENTAL
Intervention: Cachectic heart failure patients
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Noncachectic heart failure patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 79
Study: 1841609

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3000
Study: 7131001

Group type: EXPERIMENTAL
Intervention: Supine and horizontal position
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prone and horizontal position
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Supine with head-down tilt position
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Prone with head-down tilt position
Number of subjects: 76
Study: 29775119

Group type: EXPERIMENTAL
Intervention: Combined exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autologous bone marrow stem cell transplantation (ABMSCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin therapy and diabetic diet regime
Number of subjects: 30
Study: 28017455

Group type: EXPERIMENTAL
Intervention: Psychological counselling and prolonged follow-up for at least 4 weeks after discharge
Number of subjects: 0
Study: 25182045

Group type: EXPERIMENTAL
Intervention: CPAP therapy for 6 months
Number of subjects: 391

Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 391
Study: 25208464

Group type: EXPERIMENTAL
Intervention: Benralizumab (100 mg subcutaneously every 4 weeks for three doses, then every 8 weeks for five doses over 48 weeks)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 101
Study: 22764762

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 0
Study: 19354088

Group type: EXPERIMENTAL
Intervention: Atropine (2.0 mg intramuscularly) at rest (T1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline placebo before 90 minutes of intermittent exercise (T2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine before 90 minutes of intermittent exercise (T3)
Number of subjects: 7
Study: 17239866

Group type: EXPERIMENTAL
Intervention: hCG-triggered ovulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous ovulation
Number of subjects: 0
Study: 15053783

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 11356434

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg, increased to a maximum of 25 mg twice daily
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study: 9879871

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood hyperkalaemic cardioplegia with magnesium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intermittent antegrade warm blood hyperkalaemic cardioplegia only
Number of subjects: 23
Study: 7802299

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at incremental rates (30, 60, and 120 micrograms.kg‐1.min‐1)
Number of subjects: 20